Acute promyelocytic leukemia: from highly fatal to highly curable

Zhen-Yi Wang and Zhu Chen

Acute promyelocytic leukemia (APL) is a distinct subtype of acute myeloid leukemia (AML). Morphologically, it is identified as the M3 subtype of acute myeloid leukemia by the French-American-British classification and cytogenetically is characterized by a balanced reciprocal translocation between chromosomes 15 and 17, which results in the fusion between promyelocytic leukemia (PML) gene and retinoic acid receptor α (RARα). It seems that the disease is the most malignant form of acute leukemia with a severe bleeding tendency and a fatal course of only weeks. Chemotherapy (CT; daunorubicin, idarubicin and cytosine arabinoside) was the front-line treatment of APL with a complete remission (CR) rate of 75% to 80% in newly diagnosed patients. Despite all these progresses, the median duration of remission ranged from 11 to 25 months and only 35% to 45% of the patients could be cured by CT. Since the introduction of all-trans retinoic acid (ATRA) in the treatment and optimization of the ATRA-based regimens, the CR rate was raised up to 90% to 95% and 5-year disease free survival (DFS) to 74%. The use of arsenic trioxide (ATO) since early 1990s further improved the clinical outcome of refractory or relapsed as well as newly diagnosed APL. In this article, we review the history of introduction of ATRA and ATO into clinical use and the mechanistic studies in understanding this model of cancer targeted therapy. (Blood. 2008;111:2505-2515)

A historical view of acute promyelocytic leukemia (APL)

Acute promyelocytic leukemia (APL) is a distinct subtype of acute myeloid leukemia (AML, Figure 1). Morphologically, it is identified as AML-M3 by the French-American-British (FAB) classification. Cytogenetically, APL is characterized by a balanced reciprocal translocation between chromosomes 15 and 17, which results in the fusion between the promyelocytic leukemia (PML) gene and retinoic acid receptor α (RARα). Variant chromosomal translocations (eg, t(11;17), t(5;17)) can be detected in no more than 2% of APL patients. As a special entity, APL was first described in 1957 by a Swedish author, Hillestad, when he reported 3 patients characterized by “a very rapid fatal course of only a few weeks’ duration,” with a white blood cell (WBC) picture dominated by promyelocytes and a severe bleeding tendency. He concluded that the disease “seems to be the most malignant form of acute leukemia.” More detailed features of APL were described by Bernard et al5 in 1959, and the severe hemorrhagic diathesis has been ascribed to disseminated intravascular coagulation (DIC) or hyperfibrinolysis.

In 1973, Bernard et al5 demonstrated that APL leukemic cells were relatively sensitive to chemotherapy (CT; daunorubicin) that yielded a complete remission (CR) rate of 19 (55%) in 34 patients with APL. From then on, CT composed of an anthracycline (daunorubicin, idarubicin, or others) and cytosine arabinoside (Ara-C) was the front-line treatment of APL, and the CR rates could reach 75% to 80%.5,4 In newly diagnosed patients. However, the frequently observed aggravation of bleeding syndrome by CT, leading to high early death rate, necessitated intensive platelet and fibrinogen support. Despite such progress, the median duration of remission ranged from 11 to 25 months and only 35% to 45% of the patients could be cured by CT alone as judged by the criterion of 5-year disease-free survival (5-year DFS).6,39 In 1985, the introduction of all-trans retinoic acid (ATRA) opened a new page in the history of APL treatment. Optimization of the ATRA-based regimens combining ATRA and CT has further raised the CR rate up to 90% to 95%, and a 6-year DFS up to 86% (±10%) in low-risk patients in a report (Table 1). The application of arsenic trioxide (ATO) since the early 1990s further improved the clinical outcome of refractory or relapsed as well as newly diagnosed APL. A more profound reduction in PML-RARα transcript and longer survival in newly diagnosed APL were achieved when ATRA was combined with ATO compared with therapy with ATRA or ATO alone. Thus, the history of APL treatment can be subdivided into 4 periods: (1) pre-ATRA period: recognition of APL as a highly fatal disease entity and its response to CT (1957-1985) as discussed above; (2) introduction of ATRA in APL differentiation therapy and optimization of ATRA-based regimens (1985 to mid-1990s); (3) use of ATO in APL treatment (since mid-1990s); and (4) ATRA/ATO combination as a synergistic therapy and development of some new agents. In this article, we review the history of introduction of ATRA and ATO into clinical use and the mechanistic studies important in understanding this model of cancer-targeted therapy.

Introduction of ATRA as a differentiation therapy for APL: the first model of targeted therapy for cancer

In vitro studies

In the late 1970s, when studies on the treatment of acute leukemia were restarted in China after the chaos of the so-called cultural revolution, we faced a challenge in choosing a research orientation:
to find new cytotoxic CT agents or to try other strategies? Until the mid-1970s, antileukemia therapy was mainly based on CT, aiming to inhibit the proliferation of malignant cells. However, it became well known that leukemic cells possess other biologic properties such as differentiation arrest, deregulation of programmed cell death (apoptosis), and the ability to disseminate. The fact that accumulation of abnormal promyelocytes within the bone marrow is characteristic of APL strongly suggested blockage of granulocytic differentiation. A question was then raised: could approaches other than killing, such as inducing cellular differentiation, be effective in the treatment of leukemia? Two factors inspired us to orient our research to differentiation therapy. First, the disease control model in China had been influenced by the Chinese ancient philosophy on the management of society, as illustrated by Confucius’ famous saying: “If you use laws to direct the people, and punishments to control them, they will merely try to evade the laws, and will have no sense of shame. But if by virtue you guide them, and by the rites you control them, there will be a sense of shame and of right.” (Confucian Analects. Republished by Zhong-Hua-Shu-Ju, Beijing, 2005.) The translation of the essence of Confucius’ philosophy into cancer therapy could be, if cancer cells are considered elements with “bad” social behavior in our body, “educating” rather than killing these elements might represent a much better solution. Second, in Western medicine, some evidence was emerging for cancer differentiation therapy. In 1961, Pierce and Verney observed differentiation of teratocarcinoma cells. Ten years later, Friend et al. reported dimethyl sulfoxide-induced erythroid differentiation in murine virus–induced leukemia cells, while Schubert et al. demonstrated differentiation of neuroblastoma.

A major breakthrough was made by Sachs in 1978 when he discovered that leukemia cells could be triggered to undergo differentiation upon the action of certain agents. In the early 1980s, Breitman et al. described a wide variety of compounds, including butyrate, dimethyl sulfoxide, and retinoic acid (RA), which were capable of inducing morphologic and functional maturation of HL-60 cells, a line with some features of promyelocytes. They also identified the specific response of APL specimens to RA. Then, the reports by Flynn et al. and Nilsson on 2 isolated cases provided the first clues to the clinical effects of RA as a differentiation inducer for APL, since the use of 13-cis retinoic acid (13-cis-RA), an isomer of RA distinct from ATRA only in the orientation of the terminal COOH as shown in Figure 2A, induced clinical improvement or CR accompanied by maturation of promyelocytes. In 1986, Daenen et al. used 13 cis-RA to treat an APL patient who went into CR with disappearance of signs of coagulopathy. Hence, our efforts at Shanghai Rui Jin Hospital affiliated to the Shanghai Second Medical University (SSMU, now the Shanghai Jiao Tong University School of Medicine) fit well into a field where Eastern philosophy meets Western biomedical science. When we started to screen for differentiation inducers for the treatment of leukemia in 1980, we were lucky that the isomer of RA available in Shanghai at that time was ATRA, just approved by the Shanghai Municipality for the treatment of skin diseases such as psoriasis and acne, and was later on shown to be superior to 13 cis-RA in both in vitro and in vivo settings. We then

![Figure 1. Clinical and molecular characteristics of APL.](image)

The 3 features of APL are (A) a severe bleeding tendency due to fibrinogenopenia and disseminated intravascular coagulation, (B) accumulation of abnormal promyelocytes in bone marrow (top panel) and peripheral blood (bottom panel), and chromosomal translocation t(15;17)(q22;q21) (C) with the resultant fusion transcripts between PML and RARα. (D) Schematics representing the formation of 15;17 reciprocal chromosomal translocations (top panel) and fusion transcripts (bottom panel). Stains were analyzed using an Olympus BX51 research microscope equipped with a 100x/1.30 numeric aperture (NA) oil objective (Olympus, Tokyo, Japan). Images were processed using Adobe Photoshop CS (Adobe Systems, San Jose, CA). Original magnification, x1000.

<table>
<thead>
<tr>
<th>Year</th>
<th>Country</th>
<th>Reporter and reference no.</th>
<th>n</th>
<th>CR, %</th>
<th>DFS, %</th>
<th>OS, %</th>
</tr>
</thead>
<tbody>
<tr>
<td>2002</td>
<td>United States</td>
<td>Tallman et al25</td>
<td>350</td>
<td>ATRA: 70; DA: 73</td>
<td>69 (5 y)</td>
<td>69 (5 y)</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>29 (5 y)</td>
<td>45 (5 y)</td>
</tr>
<tr>
<td>2003</td>
<td>France</td>
<td>Bourgeois et al27</td>
<td>576</td>
<td>92.5</td>
<td>77 – 84 (5 y)</td>
<td></td>
</tr>
<tr>
<td>2003</td>
<td>Italy</td>
<td>Avvisati et al28</td>
<td>807</td>
<td>94.3</td>
<td>EFS (n=268): 70 (5 y)</td>
<td></td>
</tr>
<tr>
<td>2003</td>
<td>Australia</td>
<td>Iland37</td>
<td>101</td>
<td>90</td>
<td>88 (5.7 y)</td>
<td></td>
</tr>
<tr>
<td>2004</td>
<td>Spain</td>
<td>Sanz et al29</td>
<td>426 (79*)</td>
<td>90</td>
<td>81 (3 y, LPA96), 90 (3 y, LPA99), 86 (6 y*)</td>
<td></td>
</tr>
<tr>
<td>2006</td>
<td>Brazil</td>
<td>Jacomo et al30 and Ribeiro et al31</td>
<td>148</td>
<td>Mean OS of 133 pts: 1.7 y; excluding early mortality: 2.3 y</td>
<td></td>
<td></td>
</tr>
<tr>
<td>2007</td>
<td>Japan</td>
<td>Asou et al32</td>
<td>283</td>
<td>94</td>
<td>68.5 (6 y)</td>
<td>83.8 (6 y)</td>
</tr>
</tbody>
</table>

DFS indicates disease-free survival; OS, overall survival; DA, daunorubicin and cytarabine; EFS, event-free survival; and pts, patients.

*Low risk (WBC count <10 x 10⁹/L; platelet count >40 x 10⁹/L); LPA96, CT in consolidation therapy. LPA99, CT + ATRA in consolidation therapy.
demonstrated that ATRA strongly induces terminal differentiation of HL-60 and fresh APL cells. In 1985, during an informal meeting with Degos of the Institute of Hematology of Paris VII at Saint Louis Hospital, we discussed the feasibility of treating leukemia by inducing differentiation. The effects of ATRA discovered in Shanghai and that of low-dose Ara-C in Paris in inducing differentiation of leukemia cells were both appreciated. This meeting laid the foundation for a long-term cooperation between the Shanghai and Paris groups. At about the same time, SSMU sent researchers to Waxman’s lab at Mount Sinai Medical Center in New York to conduct experiments on cancer differentiation. As such, the study of APL and ATRA marked the beginning of a long intercontinental journey.

Early results of ATRA alone as a remission induction treatment for APL

The first APL patient treated with ATRA was a 5-year-old girl who received medical care in Shanghai Children's Hospital in 1985. After anthracycline-based CT, she did not achieve remission and was in critical condition with high fever, skin and mucosal hemorrhage, and septicemia with a vaginal-rectal fistula resulting from a local infection. Her parents felt that their child's condition was hopeless and wanted to abandon treatment. We suggested to them that they consider ATRA for their child and finally they agreed to try it. ATRA was administered orally at a dose of 45 mg/m² per day. After 1 week, the temperature fell to normal. Three weeks later, the girl miraculously went into CR and a postremission treatment composed of alternating ATRA/CT lasted for 1 year. Since then, she has been in remission and is now 26 years old in good health with a good career. Encouraged by the success of this pilot case, we extended the clinical trial. The first 6 APL patients (4 newly diagnosed and 2 refractory to CT) treated with ATRA all entered CR, accompanied by a gradual differentiation of leukemic promyelocytes in bone marrow and peripheral blood (Figure 2B). In 1988, the Shanghai Institute of Hematology (SIH) published in Blood the results of treatment of 24 APL patients (16 newly diagnosed and 8 refractory cases) given ATRA alone; of these, 23 cases achieved CR with differentiation of promyelocytes, while the single nonresponder also achieved CR by adding low-dose Ara-C. The efficacy of ATRA against APL was confirmed by other hematology/oncology centers worldwide. Importantly, both the European APL 91 Group and the North American Intergroup demonstrated that, although the CR rates of APL patients treated with CT alone were not significantly different from those treated with ATRA, the long-term outcome of patients treated with ATRA was better than that of the CT group. In the former study, the 12-month event-free survivals (EFSs) in ATRA and CT groups were 79% (±10%) and 50% (±9%), respectively, whereas in the latter study, the 5-year DFSs were 69% and 29%, respectively, in the ATRA and CT groups.

Optimization of regimens by combining ATRA and CT for APL treatment

Even though a CR rate of approximately 85% can be achieved in APL with ATRA alone, continuous treatment of APL with ATRA will cause progressive resistance to the drug and reduction of its plasma concentration because of accelerated clearance, resulting in relapse usually within 3 to 6 months. Furthermore, the administration of ATRA is able to induce an elevation of white blood cell (WBC) count with fatal retinoic acid syndrome (RAS). These adverse effects instigated many investigators to further optimize ATRA-based regimens for better CR rate and survival time. In the early 1990s, a multicenter clinical study on 544 cases in China clearly showed the benefits of combining ATRA and CT as part of remission induction therapy. In addition, a large number of prospective randomized studies have been conducted since the...
early 1990s, particularly by the European APL Study Group,24,27
GIMEMA (Gruppo Italiano Malattie Ematologiche dell'Adulto),28
PETHEMA (Programa de Estudio y Tratamiento de las Hemopatías
Malignas),29 the US North American Intergroup,25 and JALSG
(Japan Adult Leukemia Study Group),30 that aimed to address the
following issues: (1) Is ATRA combined with CT beneficial for
yielding better outcome and reducing the incidence of RAS?
(2) How should postremission treatment be conducted and how
long should the continuation therapy be? (3) What could be the
appropriate marker to evaluate the efficacy of ATRA therapy?
The following general conclusions have been drawn from the above-
mentioned studies.

First, ATRA/CT in combination is superior to CT or ATRA
alone, particularly with regard to reduction of relapse.25,31 CT
usually includes one anthracycline (idarubicin [I], daunorubicin
[D], mitoxantrone [M], or homoharringtonine [H]), and Ara-C and
should be started early with ATRA or when WBC count exceeds
5 to 10 × 10⁹/L. Incorporation of CT into remission induction also
reduces the incidence of RAS.32 When RAS occurs, treatment with
10 mg dexamethasone intravenously, twice daily for 3 or more
twenty-five days, tremendously reduces mortality.6,32

Second, consolidation and maintenance therapies are necessary. The
protocol recommended for consolidation is 3 monthly courses of
anthracycline-based CT,24,28-30 sometimes with high-dose Ara-C,33 while
maintenance therapy consists mostly of 6-mercaptopurine (6-MP) and
methotrexate (MTX) with ATRA for 15 days every 3 months, or
anthracycline-based CT, 6-MP + MTX, and ATRA alternately, with a
duration of usually 2 years.27,29,38 As shown in Table 1, long-term
outcome among large series of APL patients treated with optimized
ATRA-based regimens yielded 70% 5-year EFS and 6-year DFS of
68% with as high as 86% in low risk objects. The best outcome was
observed in patients who received ATRA during both induction and
maintenance with a 5-year DFS of 74%.25

Third, detection of the PML-RARα fusion transcript is not only
necessary for the diagnosis of APL, but also provides a valuable
tool for detecting minimal residual disease (MRD), revealing early
relapse after consolidation and guiding further treatment.34 Quantitative
real-time reverse-transcription–polymerase chain reaction
(RT-PCR) for analyzing PML-RARα (Figure 2C) is useful for the
assessment of the prognosis of the disease.35,36

Mechanisms of action of ATRA in APL differentiation therapy

The striking clinical benefits of ATRA in treating APL gave rise to
enthusiasm in clarifying the mechanisms of its action.

Dissecting APL leukemogenesis: transcriptional repression
leads to abnormal promyelocyte accumulation. In 1977, Rowley
et al40 from the University of Chicago reported a consistent
chromosomal translocation between chromosomes 15 and 17 in
APL. t(15;17)(q22;q21) can be detected in more than 95% of APL
patients. The breakpoints lie within the RARα locus on chromo-
some 17 and the PML locus on chromosome 15, resulting in a
combination of the 2 genes as reported by de Thé et al,41 Kakizuka
et al,42 and several other groups. The fact that the fusion transcript
of PML-RARα could be detected in 100% of patients with t(15;17)
while that of the reciprocal RARα-PML is absent in 10% to 20% of
these cases suggests an essential role for PML-RARα in leukem-
genesis. PML/RARα is able to form homodimers and sequesters
RXR and/or PML proteins in a large protein complex. The
homodimers repress the transcriptional expression of target genes
essential for granulocytic differentiation through binding to a set of
typical or variant retinoic acid response elements (RAREs) in the
regulatory region of these genes and recruiting corepressor (CoR)
proteins (such as Daxx and mSin3a/nuclear receptor corepressor
[NcoR]/histone deacetylase [HDAC]) on both PML and RARα
mioeties. In addition, recent evidence suggests that PML-RARα is
also capable of recruiting the methylating enzymes (Dnmt1 and
Dnmt3a), leading to the hypermethylation of the RA downstream
gene promoter, resulting in transcriptional repression.43 Hence, the
ultimate result of the t(15;17) as a genetic defect is an aberration
of epigenetic control in terms of both aberrant histone modification
and DNA methylation at critical gene chromatin domains. Trans-
genomic mice experiments by Pandolﬁ’s group and others showed that
the PML-RARα fusion gene expressed in myeloid lineage is crucial
for the pathogenesis of APL (He et al44), even though other genes
such as FLT-3,45 and K-ras46 are required for a fully transformed
phenotype. APL transgenic mice showed hematologic features
mirroring the human APL, including sensitivity to ATRA treatment.47

Studies on t(11;17) and PLZF-RARα as well as other variant
translocations and resultant fusion genes to further elucidate
leukemogenesis in APL. In 1991, the karyotype of a special case
of APL drew the attention of Sai-Juan Chen at SIH.47 This case was
relatively resistant to ATRA treatment. Cytogenetic analysis
revealed a t(11;17)(q23;q21) and molecular cloning by our group in
localization with Zelent and Waxman showed a fusion between
RARα and the PLZF (for promyelocytic leukemia zinc finger) gene
(Chen et al48). The PLZF-RARα fusion receptor behaves distinctly
from PML-RARα since it recruits CoR with a tighter affinity and
therefore leads to deeper transcriptional repression. A study on a
group of APL patients with t(11;17)(q23;q21) by Licht et al49
established a new entity within APL with unique biologic features
and poor prognosis. Afterward, other variant translocations were
also reported, including t(5;17)(q35;q21), where RARα was fused
with nucleophosmin (NPM1); t(11;17)(q13;q21), in which a fusion
gene nuclear matrix–associated (NuMA)–RARα was formed; and
dup17(q11;q21), which generated a Stat5b-RARα fusion.50,51 A
common feature of all fusion RA receptors in APL is that they are
able to form homodimers with higher affinity for the CoR complex.
Transgenic mouse models were reported for PLZF-RARα, NPM-
RARα, and NuMa-RARα, and all these models resulted in leuko-
emia. Interestingly, PLZF-RARα leukemic mice displayed partial
resistance to ATRA at both cellular and organism levels.52

Mechanisms of action of ATRA. The discovery of PML/RARα
in APL pathogenesis pointed to a possible molecular mechanism
underlying ATRA-specific therapy. Indeed, PML–RARα is a “drug-
gable” target. It is generally accepted that a pharmacological
concentration (10⁻⁶–10⁻⁷ M) of ATRA causes a configuration
change of PML-RARα. As a result, the CoR complex dissociates
from the receptor, whereas a coactivator complex composed of
proteins with histone acetylase (HAT) activity is recruited, opening
the chromatin structure and relieving transcriptional repression.
This coregulator exchange model seems to get support from recent
transcriptome and proteome analyses,53 with modulation of a large
number of genes involved in the initiation/promotion of granulo-
cytic differentiation, such as the up-regulation of granulopoiesis-
associated transcription factors C/EBPs, cytokines/cytokine recep-
tors, as well as their corresponding postreceptor signal transduction
molecules. It is worth noting that another effect of ATRA in
modulating PML-RARα is to induce its degradation. Although it
was reported that ATRA could trigger caspase-mediated cleavage
of the PML–RARα chimeric protein,54 further dissection of the
pathways involved in PML–RARα catabolism led to the discovery of
a ubiquitin/ proteasome system (UPS)–mediated degradation of
PML–RARα and RARα, which was dependent on the binding of
SUG-1 in the AF-2 transactivation domain of RARα.55,56 Indeed, a
number of components of the UPS necessary for the degradation of PML-RARα can be significantly enhanced upon ATRA. Moreover, in leukemic cells with PLZF-RARα, exposed to even 10⁻⁵ M of ATRA, the coregulator exchange is not sufficient, while the HDAC inhibitors TSA (trichostatin) or SAHA (suberoylanilide hydroxamic acid) cannot only reverse the transcriptional repression but also allow terminal differentiation of t(11;17) cells in combination with ATRA.

Use of ATO in the treatment of APL: taming an evil with a toxic agent

History of arsenic as a drug

Arsenic is a common, naturally occurring substance that exists in organic and inorganic forms. There are 3 inorganic forms of arsenic: red arsenic (As₂S₃, also known as realgar); yellow arsenic (As₂S₅, also known as orpiment); and white arsenic or ATO (As₂O₃), which is made by burning realgar or orpiment (Figure 3).

Although a well-known poison, arsenic is also one of the oldest drugs in both Western medicine and traditional Chinese medicine (TCM), since it was mentioned by Hippocrates (460–370 BC) for treatment of skin ulcer and by the Chinese Treaty Neijing (263 BC) for treatment of malaria-associated periodic fever. In the late 18th and early 19th centuries, arsenic, in the form of Fowler solution (potassium bicarbonate–based solution of arsenic), was introduced to treat periodic fever, chronic myelogenous leukemia (CML), and many other diseases. However, it was discarded as a treatment in the early 20th century because of its toxicity and the advent of radiation and cytotoxic CT.

Arsenic in APL treatment

In TCM, arsenic is applied to only severe diseases with the principle of “taming an evil with a toxic agent.” In the early 1970s, a group from Harbin Medical University in northeastern China identified ATO as an active ingredient from an anticancer remedy and then used an arsenic compound to treat a variety of cancers. In 1992, Sun et al. reported that, by administration (intravenous) of a crude solution of ATO composed of 1% ATO with a trace amount of mercury chloride, 21 of 32 APL patients entered CR with an impressive 30% survival rate after 10 years. In 1996 to 1997, groups from Harbin and SIH reported respective results using pure ATO in treating APL. In the Harbin series, CR rates of 73% and 52% were obtained in 30 newly diagnosed and 42 relapsed APL cases, respectively. From SIH, 15 APL patients at relapse after ATRA/CT received ATO at a dose of 0.16 mg/kg per day intravenously for 28 to 54 days. CR was achieved in 9 (90%) of 10 patients treated with ATO alone and in the remaining 5 treated by the combination of ATO and low-dose CT drugs or ATRA. During the treatment with ATO, there was no bone marrow depression and only limited side effects were encountered. These results were further confirmed by SIH in a larger group of 47 relapsed and 11 newly diagnosed APL cases with CR rates of 85.1% and 72.7%, respectively, and then by many groups worldwide. Furthermore, after CR is achieved by ATO alone, a molecular remission is obtainable in a relatively high proportion of the patients, from 72% to 91% in different multicenter studies, demonstrating that ATO is a highly effective drug for APL. Using ATO as a single agent, a relatively good long-term remission can be obtained in newly diagnosed patients, as evidenced by a 2-year DFS of 63.7% and a 3-year DFS of 87.2% in 2 recent studies.

It is worth noting that another arsenic compound, As₂S₃, was also effective in the treatment of APL. Clinical use of As₂S₃ can be either in composite formulas as a standard practice of TCM or as a single agent. In 1995, Huang et al. introduced orally used “composite Realgar-indigo naturalis tablets” for APL treatment, which contain realgar, indigo naturalis, Radix salviae miltiorrhizae, and Radix pseudostellariae. A CR rate of 98% was achieved in 60 APL patients. This result was recently confirmed by a multicenter study in China and a CR rate of 96.7% was achieved in a series of 78 cases.

On the other hand, Lu et al. reported in 2002 that by using pure As₂S₃, 103 (79.8%) of 129 APL patients achieved CR. There were 19 newly diagnosed APL cases in that series and all these cases obtained CR.

Mechanisms of action

Before the first controlled clinical trial of ATO in APL, SIH conducted a study on the cellular and molecular mechanisms of action of this ancient remedy. Interestingly, ATO exerts dose-dependent effects on APL cells. Under high concentration (1-2 × 10⁻⁶ M), ATO induces apoptosis, mainly through activating the mitochondria-mediated intrinsic apoptotic pathway. Under low concentrations (0.25-0.5 × 10⁻⁶ M) and with a longer treatment course, ATO tends to promote differentiation of APL cells. Since a range of ATO concentrations could exist in vivo as revealed by pharmacokinetic studies, we proposed that induction of both apoptosis and differentiation be a possible cellular mechanism in the clinical setting. This point of view was then supported by examination of bone marrow under ATO treatment in APL patients and in the PML-RARα/APL mouse model. The mechanism of proapoptotic activity of ATO was further scrutinized by many groups at the gene/protein levels, and a large body of information has been gathered, including histone H3 phosphoacetylation at Kasparase-10, the involvement of JNK signaling, anion exchanger 276 and GSTP1-1,77 up-regulation of a set of genes responsible for reactive oxygen species (ROS) production, intracellular oxidative DNA damage, suppression of human telomerase reverse transcriptase gene (hTERT), C17, and c-Myc genes through Sp1 oxidation, repression of NFκB activation, and down-regulation of Wt1 gene. Recently, a pathway composed of ATR, PML, Chk2, and p53 has been proposed to mediate ATO-induced apoptosis.

The fact that ATO exerts selective therapeutic effects against APL but not against other subtypes of leukemia suggests a crucial link between its mechanism of action and PML-RARα. Indeed, we found that both PML-RARα and wild-type PML, but not wild-type RARα, were induced to be degraded in APL cells.

From www.bloodjournal.org by guest on July 17, 2015. For personal use only.
upon ATO in vitro and in vivo. This observation suggests that ATO might target the PML moiety in the fusion protein. Subsequent studies by several groups found that treatment of APL cells with ATO led to a significant degree of sumoylation of PML and PML-RARα/H9251. It was shown that sumoylation might take place at amino acids K65, K160, and K490, but only lysine 160 was important for the effect of ATO, since it mediated not only sumoylation but also subsequent recruitment of 11S proteasome, a process essential for the degradation of PML and PML-RARα proteins. When transcriptome/proteome platforms were used to analyze the effect of ATO and the data were compared with those of ATRA, we made an interesting observation: ATO could regulate a significant proportion of genes also modulated by ATRA, but the extent of modulation was much less than that by ATRA. In contrast, ATO induces a deeper change of proteome pattern, suggesting that protein modification, rather than gene expression modulation, could be the major molecular mechanism of ATO.

ATRA/ATO combination as a synergistic therapy and development of some new agents for APL-targeted therapy

Combination of ATRA and ATO in taming APL

Rationale. In 1998, at a meeting in Shanghai with Degos and Waxman, we discussed the possibility of using a triad of CT, ATRA, and ATO for newly diagnosed patients in an attempt to maximize the 5-year DFS in APL. Subsequently, in a PML/RARα mouse model and a human NB4 APL cell line–based ascites/leukemic mouse model, de Thé’s group (Lallemand-Breitenbach et al84) and a group jointly led by Waxman and us (Jing et al83) showed that this combination could dramatically prolong the survival or even eradicate disease in animals. These results encouraged us to conduct a clinical trial using ATRA/ATO combination to treat newly diagnosed APL.

Marked clinical benefits. A randomized study with ATRA or ATO as a single agent or in combination for remission induction, followed by CT consolidation/continuation, was carried out at SIH beginning in April 2000 and the results were published in 2004.65 Sixty-one APL subjects were randomized into 3 groups treated with (1) ATRA, (2) ATO, or (3) the combination of the 2 drugs. The tumor burden was examined with real-time RT-PCR for the PML-RARα transcripts. Although CR rates in the 3 groups were similar (≥ 90%), the time to achieve CR was much shorter in the combination group than in the others (P < .05). The disease burden reflected by a fold change of PML-RARα transcripts at CR decreased more significantly in the combination therapy group compared with the monotherapy groups (P < .01; Figure 2C). This difference persisted after consolidation (P < .05). Importantly, all 20 cases in the combination group remained in CR, whereas 7 of 37 cases treated with monotherapy relapsed (P < .05) after a medium follow-up (MFU) of 18 months (range: 8-30 months). In 2006, we reported the results of 56 newly diagnosed APL patients treated with ATRA/ATO/CT since 2001 with an MFU of 48 months and compared the data with the conventional ATRA-ATO
transition treatment group of 56 relatively well-matched cases treated by ATRA/CT and then ATO at relapse. The 4-year DFS and the 4-year overall survival (OS) rates in the study group were estimated at 94.2% (± 3.3%) and 98.1% (± 1.8%), respectively, compared with those of 45.6% (± 7.6%) and 83.4% (± 5.4%), respectively, in controls (P < .001 and P = .012, respectively).66 Our recent most data with an MFU of 60 months in these 2 groups showed a similar situation (Figure 4; Y. F. Liu, J. Hu, S. J. Chen, Z.C., unpublished data, June 2007). These results, together with some recent reports from other centers,87,88 clearly demonstrate superiority in treating APL simultaneously with ATRA and ATO.

Mechanisms of synergistic effect in combination therapy.

Applying an approach integrating cDNA microarray, proteomics, and methods of computational biology to study the effects on APL cells treated with ATRA and/or ATO, it was revealed that ATRA-induced differentiation involves essentially transcriptional remodeling, while the effects of ATO reside mainly at the proteome level, creating a molecular foundation for the synergistic/addictive effects between ATRA and ATO.55 The ATRA/ATO combination amplifies RA signaling, as highlighted by molecules involving IFN, calcium, cAMP/PKA, MAPK/JNK/p38, G-CSF, and TNF pathways. ATRA/ATO combination strongly activates the ubiquitin-proteasome pathway and significantly represses genes/proteins promoting cell cycling or enhancing cell proliferation, which plays a central role in APL leukemogenesis, while a common point mutation in the tyrosine kinase II domain can be detected in 25% to 30% of APL cases;60,61 therefore, a crosstalk could exist between ATO and ATRA signaling pathways through a CAMP/PKA node. Importantly, enhanced degradation of PML-RARα oncoprotein might provide a plausible explanation for the superior efficacy of combination therapy in patients. The 2 agents target distinct moieties of the oncoprotein: ATO on PML, versus ATRA on RARα, and have different molecular mechanisms. In agreement with this, recent studies showed that ATRA is able to increase the cell membrane arsenic channel aquaglyceroporin 9 (AQP9) level, which allows more arsenic to enter into cells.65 Figure 5 summarizes possible focal points for the effects of ATRA in combination with ATO.

New agents for APL-targeted therapy

**Humanized anti-CD33 monoclonal antibodies (mAbs).** High-density cell surface membrane expression of the CD33 differentiation antigen is detectable in almost 100% of APL patients. Gemtuzumab ozogamicin is an anti-CD33 antibody calicheamicin-conjugate. Used as a single agent for the treatment of relapsed APL, molecular remission was obtained in 9 (81.8%) of 11 patients tested after 2 doses and in 13 (100%) of 13 patients tested after the third dose.66 Another anti-CD33 mAb, HuM195, has been shown to eliminate MRD in 11 (50%) of 22 cases in a recent trial.97

**FLT3 inhibitor.** The FLT3 gene encodes a type III receptor tyrosine kinase. Internal tandem duplication in the juxtamembrane domain and point mutation in the tyrosine kinase II domain can be detected in 25% to 45% of APL patients.43,98 FLT-3 inhibitor SU11657 in combination with ATRA could cause a rapid regression of leukemia in the APL mouse model,49 but to date it has not been evaluated in a clinical study.43

### Table 2. Important events in transforming APL from being a highly fatal to a highly curable disease

<table>
<thead>
<tr>
<th>Recognition of APL as a unique subtype of acute leukemia</th>
</tr>
</thead>
<tbody>
<tr>
<td>In 1957, Hillestad1 first reported 3 patients with a highly fatal disease, which he designated as APL. APL was named AML M3100 in 1976.</td>
</tr>
<tr>
<td>In 1977, I(15;17)(q22;q21) was identified,61 while the PML-RARα fusion gene was cloned41,42 in 1991. The variant translocations, eg, t(11;17)(q23;q21),47,48 t(5;17)(q55;q21),101 t(11;17)(q13;q21),102 and dup(17)(q11;q21),103 were subsequently discovered.</td>
</tr>
</tbody>
</table>

### Development of curative therapeutic approaches for APL

Pre-ATRA period

CT was first used against APL in 1967, and anthracycline was introduced to treat APL in 1973.3

Incorporating ATRA in treating APL

Early results: ATRA was used to treat APL in 1985. In 1987, its efficacy on the first 6 patients was reported17; in 1998, Huang et al18 showed the high CR rate induced by ATRA in 24 APL cases. Clinical results using ATRA in treating APL in Western countries were reported in 1990.19,21

International joint efforts in optimizing ATRA-based regimen: Since 1990, ATRA has been used in combination with CT, resulting in CR rates up to 90%—95%, and 5-year DFS up to 74%,24,25,27,30,104

Studies on mechanisms of action of ATRA: In 1996, PML-RARα was shown to be a direct target of ATRA.105 ATRA-triggered degradation of PML-RARα was then shown to be mediated by caspases94 and proteasome.107 In 2000, gene expression networks underlying ATRA-induced APL cell differentiation were investigated, and many retinoic acid–induced genes were identified.108

Incorporating ATO in treating APL

In 1992, Sun et al9 reported the efficacies of Ailing–1—a crude solution of ATO—in treating APL. In the mid-1990s, Chen et al9 showed the cAMP-PKA node, and cAMP-dependent dual effects of ATO on APL cells, in which degradation of PML-RARα and cooperates with ATO to induce apoptosis.91 In APL cells, ATRA induces degradation of the Nfkb inhibitor Iκb, while ATO antagonizes Iκb catabolism and consequently decreases Nfκb activation.80 It is worth noting that ATO alone induces partial differentiation of APL cells,61 and the 2-step model for differentiation induction suggests that cyclic adenosine monophosphate (cAMP) should be incorporated for induction of terminal differentiation of APL cells.92 This notion was confirmed by Zhu et al93 who showed that a strong synergy exists between a low concentration of ATO (0.25 μM) and cAMP analog 8-CPT-cAMP in fully inducing differentiation of ATRA-sensitive and ATRA-resistant APL cell lines and fresh APL cells. Interestingly, ATRA rapidly triggers a marked increase in intracellular cAMP level and cAMP-dependent protein kinase (PKA) activity.94 Therefore, a crosstalk could exist between ATO and ATRA signaling pathways through a CAMP/PKA node. Importantly, enhanced degradation of PML-RARα oncoprotein might provide a plausible explanation for the superior efficacy of combination therapy in patients. The 2 agents target distinct moieties of the oncoprotein: ATO on PML, versus ATRA on RARα, and have different molecular mechanisms. In agreement with this, recent studies showed that ATRA is able to increase the cell membrane arsenic channel aquaglyceroporin 9 (AQP9) level, which allows more arsenic to enter into cells.95 Figure 5 summarizes possible focal points for the effects of ATRA in combination with ATO.

### Development of new agents

- **New agents for APL**
  - **Humanized anti-CD33 monoclonal antibodies (mAbs).** High-density cell surface membrane expression of the CD33 differentiation antigen is detectable in almost 100% of APL patients. Gemtuzumab ozogamicin is an anti-CD33 antibody calicheamicin-conjugate. Used as a single agent for the treatment of relapsed APL, molecular remission was obtained in 9 (81.8%) of 11 patients tested after 2 doses and in 13 (100%) of 13 patients tested after the third dose. Another anti-CD33 mAb, HuM195, has been shown to eliminate MRD in 11 (50%) of 22 cases in a recent trial.
  - **FLT3 inhibitor.** The FLT3 gene encodes a type III receptor tyrosine kinase. Internal tandem duplication in the juxtamembrane domain and point mutation in the tyrosine kinase II domain can be detected in 25% to 45% of APL patients. FLT-3 inhibitor SU11657 in combination with ATRA could cause a rapid regression of leukemia in the APL mouse model, but to date it has not been evaluated in a clinical study.

### Conclusion and perspectives

APL has a unique and specific chromosomal aberration t(15;17) resulting in the formation of a fusion gene and protein PML/RARα, which plays a central role in APL leukemogenesis, while a common pharmacological activity is shared by ATRA and ATO, that is, to modulate and/or degrade the fusion protein PML/RARα. Therefore, the success of ATRA and ATO in APL treatment furnishes the first model of molecular target–based induction of differentiation and apoptosis, ahead of targeting therapy with imatinib mesylate for CML. The recent results of both high CR rates (90%—94%) and high 5-year DFS rates (> 90%)}
using ATRA/ATO/CT in APL are comparable with the best results already achieved in childhood acute lymphocytic leukemia. Because of the great efforts made by the international scientific community (Table 2), the molecular understanding of the APL disease mechanism and the mode of action of ATRA/ATO has been explored in a systematic way to establish a model of changing cellular transcriptional regulations in both leukemogenesis and in designing efficient therapy. All these achievements show the power of integrating Western and Eastern wisdoms and make us confident that APL status has evolved from highly fatal to highly curable. The experiences acquired in taming APL are probably useful in that they mirror the way to conquer other types of leukemia and even the nonhematologic malignancies.

Acknowledgments

The authors thank Dr Guang-Biao Zhou from the Guangzhou Institute of Biomedicine and Health, Chinese Academy of Sciences, for the critical review of the article and Dr Laurent Degos from Hospital Saint Louis in Paris and Dr Samuel Waxman from Mount Sinai Medical Center in New York for their friendly long-term collaboration.

This work was supported in part by the Chinese National Key Program for Basic Research (973) and the National High Tech Program (863), National Natural Science Foundation of China, Shanghai Municipal Commission for Science and Technology, the Shanghai Municipal Commission for Education, and the Samuel Waxman Cancer Research Foundation.

Authorship

Contribution: Z.-Y.W. and Z.C. wrote the article.

Conflict-of-interest disclosure: The authors declare no competing financial interests.

Correspondence: Zhen-Yi Wang, Shanghai Institute of Hematology, Rui Jin Hospital affiliated to Shanghai Jiao Tong University School of Medicine, 197 Rui Jin Rd II, Shanghai, 200025, China; e-mail: xiejx@public2.sta.net.cn; Zhu Chen, Ministry of Health, PR. China, No. 1 South Xizhimenwai Rd, Xicheng District, Beijing, 100044, China; e-mail: zchen@stn.sh.cn.

References

36. Gu BW, Hu J, Xu L, et al. Results of the APLM3 trial of ATRA, intensive idarubicin and triple maintenance combined with molecular monitoring in acute promyelocytic leukemia (APL): a study by the Australasian Leukemia and


Although leukemia was the most common disease in the hematology department of Rui-Jin hospital, therapeutic options for acute myeloid leukemia (AML) were very limited and therapies usually failed, and clinical outcome was even worse for patients with acute promyelocytic leukemia (APL). These grave facts prompted Wang to further explore therapeutic strategies for AML. Unfortunately, he was treated as a “reconstruction academic authority” during the Cultural Revolution (1967-1978) and had to quit his research for 11 years. Afterward he resumed his work in trying to develop a therapeutic approach for AML, but he faced a challenge in choosing the research orientation: to find new cytotoxic chemotherapy agents or to try other strategies? Wang was enlightened by ancient Chinese philosophy. “Cancer cells are ‘bad elements’ within our body,” he thought; “can they be ‘educated’ to return to normal, so that cancer can be treated without killing?”. He found his idea met well with the emerging concept of cancer differentiation therapy, and he contributed great efforts to screen for differentiation inducers using APL cell lines and primary cells isolated from patients. “We were extremely lucky in that the isomer of retinoic acid available in Shanghai at that time was the all-trans retinoic acid (ATRA),” he said, “and we found that ATRA triggers a terminal maturation of APL cells. The intriguing in vitro data were the impetus for us to conduct a clinical trial.” His group introduced ATRA in treating APL in 1985, and reported the dramatic efficacy in Blood in 1988. Their results were progressively recognized worldwide, and hundreds of thousands of APL patients benefit from this achievement.

Wang received the Kettering Prize from the General Motors Cancer Research Foundation USA in 1994, the Prize of Brupbacher from Switzerland in 1997, the Prize for Science from the Simmon Del Duca Foundation of France in 1998, and the Lecture Award of Ham-Wasserman from the American Society of Hematology in 2003. He was made an Honorary Doctor of Science by Columbia University in 2001, and received the Outstanding Mentor Award from the Shanghai Municipal government in 2003. He was elected a Foreign Associate member of the French Academy of Sciences in 1992 and a member of the Chinese Academy of Engineering in 1994. He has published more than 300 papers, in which he is the first author in about 40. He is now a Professor Emeritus at Shanghai Jiao Tong University School of Medicine and honorary Director of the Shanghai Institute of Hematology, Rui-Jin Hospital. He is still dedicated to hematology, particularly to researching leukemogenesis and targeted therapies for other subtypes of leukemia.

Dr Zhu Chen grew up in a family of doctors in Shanghai, China. He left school in 1966 because of the Cultural Revolution and went to a remote rural village where he educated himself and worked as both a farmer and a “barefoot” doctor. He entered a 2-year medical course in 1975 and received advanced training at Rui-Jin Hospital Affiliated to Shanghai Second Medical University (now called Shanghai Jiao Tong University School of Medicine). Here he
met Dr Zhen-Yi Wang, a hematologist. Two factors quickly led Chen to choose hematology as his career. The first was purely scientific, as he recalled: “I initially thought that hematology was a difficult discipline in that remedies for diseases like leukemia and hemophilia were limited, while the pathogenesis was elusive. But when I read advanced literature I realized this could be changed thanks to advances in immunology, biochemistry, and molecular biology. The discoveries in hemoglobinopathy pathogenesis predicted similar breakthroughs in leukemia and hemophilia.” The second factor was the restoration of the formal education program in China. Under Wang’s supervision, Chen carried out 3 years’ research on several disparate diseases and published procedures for detection and discrimination of hemophilia A carriers and variants of von Willebrand disease. He also focused on cell culture in leukemia and gained great interest in therapeutic approaches such as immunotherapy and differentiation therapy for cancer.

After graduate studies and an internship at Rui-Jin Hospital from 1981 to 1984, Chen relocated to the Central Hematology Laboratory at Saint-Louis Hospital (Paris), where he spent his first year as a visiting intern and worked with Jean Bernard, Jean Dausset, Michel Boiron, Georges Flandrin, Francois Sigaux, and Laurent Degos of the University of Paris VII. Between October 1985 and January 1989 he completed his PhD and continued postdoctoral studies concerning the rearrangement and expression of T cell receptor (TCR) genes in human leukemia and characterized part of the TCRgamma chain region, participated in the work on several oncogenes, and published extensively on many different aspects of leukemia. “Those years in Paris were a second leap forward in my research career as a hematologist. Although I learned quite a lot about molecular biology, I never forgot the patients. Of course, this period also allowed me to accumulate international experiences, which are essential in advancing science,” Chen said. During his stay in Paris, Chen kept in close contact with Wang, who informed him of all the progress in Shanghai, particularly the work showing that all-trans retinoic acid (ATRA) was successful in treating acute promyelocytic leukemia (APL), the M3 subtype of acute myeloid leukemia, through induction of maturation of abnormal promyelocytes. Chen and his wife, Dr Sai-Juan Chen, were deeply interested in these results and wanted to elucidate the molecular basis of APL pathogenesis and differentiation therapy, so in July of 1989 Chen returned to China to take up a post at the Shanghai Institute of Hematology at Rui-Jin Hospital. By further analyzing the genetics and phenotype of APL, Chen’s group identified the first variant chromosomal translocation t(11;17) with RARalpha fused to a distinct partner, PLZF, in a subset of APL that is resistant to ATRA. Chen and his collaborators carried out comparative studies between t(15;17) and t(11;17) that helped reveal a key mechanism in ATRA action: the modulation of aberrant RARalpha proteins and their coregulators. He studied gene expression networks underlying retinoic acid–induced differentiation and identified many retinoic acid–induced genes (RIGs) that were shown to have important biological functions.

In the mid-1990s, Chen and colleagues were first to demonstrate that arsenic trioxide (ATO) modulates PML-RARalpha oncoprotein and exerts dose-dependent dual effects on APL cells (eg, triggers differentiation at low doses and induces apoptosis at greater concentrations). They published results of the first controlled clinical trial using purified ATO and showed the efficacy of ATO in treating relapsed APL patients, and described for the first time the pharmacokinetics of ATO in vivo. In 2000, after analyzing rationales with his collaborators, Chen initiated a trial using ATRA/ATO combination in treating newly diagnosed APL, and reported in 2004 that a shorter time to achieve CR, a more profound reduction in PML-RARalpha transcript, and particularly much less relapse of disease were obtained in patients treated with ATRA in combination with ATO as compared with treatment with ATRA or ATO alone as remission induction. Chen also contributed to the Human Genome Project and Human Cancer Genome Project, and to systems biology research in China. He trained many young researchers who are now principle investigators in hematology/oncology or genomics in China, the US, and other countries. He was the Vice President of the Chinese Academy of Sciences from 2000 to June 2007, and was then appointed as the Minister of Health of Chinese government.
Acute promyelocytic leukemia: from highly fatal to highly curable

Zhen-Yi Wang and Zhu Chen